Japan Approves Ligand Drug

Xconomy San Diego — 

San Diego’s Ligand Pharmaceuticals (NASDAQ: LGND) says Japan’s Ministry of Health, Labor, and Welfare gave its approval to Ligand partner GlaxoSmithKline’s (NYSE: GSK) application for eltrombopag (Revolade), a drug developed to treat a blood disorder called chronic idiopathic thrombocytopenic purpura (ITP). Ligand says eltrombopag is the first oral treatment that stimulates the production of blood platelets, considered essential to normal clotting. ITP patients experience bruising and bleeding and, in some cases, serious hemorrhages, which can be fatal.